Navigation Links
PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
Date:6/16/2008

s dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 as filed with the SEC on May 9, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contacts:

Jennifer Baird, Senior Director of Public Relations

PAREXEL International

Tel: +781-434-5033

Email: Jennifer.Baird@PAREXEL.com

Rebecca Passo

SHIFT Communications


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PAREXEL Reaches Agreement To Acquire ClinPhone
2. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
3. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
4. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
5. PAREXEL Reports Third Quarter Fiscal Year 2008 Financial Results
6. PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference
7. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
8. PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
9. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
10. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
11. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... YORK , May 21, 2015  Susan ... Research (FPWR), a nonprofit organization dedicated to supporting ... Prader-Willi syndrome (PWS), announced today that FPWR has ... and Irina Shaulov contributed $1 million ... clinical initiatives.  ...
(Date:5/21/2015)... Germany (PRWEB) May 21, 2015 ... that its manufacturing facility in Worms, Germany has ... an independent subsidiary of the International Pharmaceutical Excipient ... Grace facilities that produce its SYLOID® FP brand ... received GMP certification, following the Curtis Bay, Maryland ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 This year ... especially for lawns. US Patented Pearl’s Premium Ultra ... lawns around the country that are coming out of ... addresses a number of major global concerns related to ... “non-grass” grass – the alternative to the standard, water-wasting, ...
Breaking Biology Technology:The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
... CALL DATE: Wednesday, Aug. 6, 2008 TIME: ... Dr. Candace Kendle, Chairman and CEO, ... call and,simultaneous webcast on Wednesday, Aug. 6 at 9:30 a.m. Eastern ... 30, 2008. A,question and answer session will follow., Webcast Instructions, ...
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced ... Daiichi Sankyo), has received marketing,approval from the Japanese ... label extension of Biopten(R) (sapropterin dihydrochloride), which,contains the ... for the,treatment of patients with phenylketonuria (PKU). BioMarin ...
... Consent Judgment Terminating Litigation --, MADISON, N.J., ... and,Impax Laboratories Inc. today announced that all conditions ... pertaining to Impax,s proposed,generic capsule formulation of Wyeth,s ... States District Court for the District of,Delaware. The ...
Cached Biology Technology:Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast 2Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 2Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 3Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 4Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit 2Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit 3
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... by a combination of genetic and environmental factors. For ... external influences. According to scientists from the Max Planck ... not harmful bacteria that trigger multiple sclerosis, but ... every human being needs for digestion. The researchers ...
... -- On Friday, Oct. 28 2011 the research icebreaker ... 200 scientists and technicians from research institutions in 14 ... They will examine a wide variety of topics: oceanography ... bacteria, tiny algae and animals all the way to ...
... DIEGO (Oct.27, 2011) The La Jolla ... fifth organization in the prestigious Sanford Consortium for ... for Biological Studies, The Scripps Research Institute, University ... Research Institute in the first-of-its-kind multi-institutional stem cell ...
Cached Biology News:Natural intestinal flora involved in the emergence of multiple sclerosis 2Natural intestinal flora involved in the emergence of multiple sclerosis 3RV Polarstern launches 28th Antarctic season 2La Jolla Institute joins Sanford Consortium for Regenerative Medicine 2La Jolla Institute joins Sanford Consortium for Regenerative Medicine 3
Request Info...
... are available in two product models - the ... models is that the 6000AT+ includes a membrane ... aerosol for improved detection limits and reduced oxides. ... range of elements by 10-40 times. Note that ...
... of RNase A-type ribonucleases Product Description: ,QIAGEN ... origin that binds noncovalently and inactivates a ... and C). It does not interfere with ... CL3. QIAGEN RNase Inhibitor inhibits greater than ...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
Biology Products: